Maplight Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
MapLight Therapeutics, a clinical-stage biopharmaceutical company, is launching its initial public offering to fund the advancement of its central nervous system disorder pipeline, despite ongoing substantial losses and a 'going concern' warning.
NASDAQ
Clinical-stage biopharmaceutical company MapLight Therapeutics files S-1 for initial public offering to advance CNS disorder therapies, including lead candidates for schizophrenia and Alzheimer's psychosis.